Drug combo for ER-low, HER2-negative metastatic breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three drugs (albumin-bound paclitaxel, dalpiciclib, and an aromatase inhibitor) as a first treatment for women with ER-low, HER2-negative breast cancer that has spread and cannot be removed with surgery. The goal is to see if this combination helps control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have breast cancer with low estrogen receptor (ER) levels (between 1% and 10%) that has come back or spread, and your cancer is HER2-negative.
- You have not had any previous cancer treatment for cancer that has spread.
- You are a woman between 18 and 75 years old. If you are still having periods, you are willing to take a medicine to stop them temporarily.
- You have not taken a CDK4/6 inhibitor drug before.
- You are generally well enough to be active (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs (dalpiciclib and an HDAC inhibitor) for people with HR+/HER2- advanced breast cancer whose disease has progressed after prior CDK4/6 inhibitor treatment. The goal is to see if this new combination can help control the cancer.
This trial tests a combination of three drugs—dalpiciclib (a new cell-cycle inhibitor), anti-HER2 therapy, and hormone therapy—for advanced breast cancer that is positive for both hormone receptors and HER2 protein. The goal is to help patients whose cancer has responded to initial treatment stay in remission longer.
This trial tests a new combination of two drugs (dalpiciclib and letrozole) as a first treatment for advanced breast cancer that is hormone receptor positive and HER2 negative. It aims to find the best dose to slow or stop cancer growth.
This study tests whether combining two drugs (dalpiciclib and SHR-A1811) before surgery can shrink early-stage breast cancers that are hormone-sensitive and HER2-low. The goal is to see if this approach improves outcomes for patients with intermediate-to-high risk disease.
This trial tests a combination of three drugs (dalpiciclib, letrozole, and anlotinib) given before surgery to postmenopausal women with stage II or III HR+/HER2- breast cancer. The goal is to see if this neoadjuvant treatment shrinks tumors and improves outcomes.
This Phase 2 trial tests dalpiciclib (a cancer medicine) added to standard hormone therapy for women with advanced, hormone-receptor–positive and HER2-negative breast cancer that has serious “visceral crisis” symptoms (like fluid buildup, liver issues, or other urgent organ involvement). It aims to see whether this combination can shrink cancer and improve safety compared with hormone therapy alone.
Hear when a new Advanced HR+/HER2- Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.